Premium
Aggressive myoepithelial carcinoma with EWSR1‐POU5F1 fusion highly responsive to Ewing sarcoma combination chemotherapy
Author(s) -
Shenoy Niraj
Publication year - 2020
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.33220
Subject(s) - medicine , sarcoma , regimen , oncology , myoepithelial cell , chemotherapy , carcinoma , pathology , immunohistochemistry
This article describes a case of metastatic, bulky, high‐grade, rapidly progressive myoepithelial carcinoma with EWSR1‐POU5F1 fusion originating from the left kidney that demonstrated a dramatic, deep response within 2 cycles of treatment with a regimen used for patients with Ewing sarcoma and an ongoing sustained response of >10 months. To the author's knowledge, this is the first report of a rapid and deep response using a systemic therapy regimen in a patient with myoepithelial carcinoma with EWSR1‐POU5F1 fusion.